Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program

Alain H. Litwin, Irene J. Soloway, Lauren Cockerham-Colas, Sheila Reynoso, Moonseong Heo, Christopher Tenore, Robert J. Roose

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: People who inject drugs (PWID) constitute 10 million people globally with hepatitis C virus, including many opioid agonist treatment patients. Little data exist describing clinical outcomes for patients receiving HCV treatment with direct-acting antiviral agents (DAAs) in opioid agonist treatment settings. Methods: In this retrospective observational study, we describe clinical outcomes for 50 genotype-1 patients receiving HCV treatment with triple therapy: telaprevir (n = 42) or boceprevir (n = 8) in combination with pegylated interferon and ribavirin on-site in an opioid agonist treatment program. Results: Overall, 70% achieved an end of treatment response (ETR) and 62% achieved a sustained virological response (SVR). These treatment outcomes are nearly equivalent to previously published HCV outcomes shown in registration trials, despite high percentages of recent drug use prior to treatment (52%), ongoing drug use during treatment (45%) and psychiatric comorbidity (86%). Only 12% (n = 6) discontinued antiviral treatment early for non-virological reasons. Four patients received a blood transfusion, and one discontinued telaprevir due to severe rash. Conclusions: These data demonstrate that on-site HCV treatment with direct-acting antiviral agents is effective in opioid agonist treatment patients including patients who are actively using drugs. Future interferon-free regimens will likely be even more effective. Opioid agonist treatment programs represent an opportunity to safely and effectively treat chronic hepatitis C, and PWID should have unrestricted access to DAAs.

Original languageEnglish (US)
Pages (from-to)1014-1019
Number of pages6
JournalInternational Journal of Drug Policy
Volume26
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Chronic Hepatitis C
Opioid Analgesics
Antiviral Agents
Therapeutics
Pharmaceutical Preparations
Interferons
Personal Autonomy
Ribavirin
Exanthema
Blood Transfusion
Hepacivirus
Observational Studies
Psychiatry
Comorbidity
Retrospective Studies
Genotype

Keywords

  • Direct-acting antiviral agents
  • HCV
  • IDU
  • Injection drug users
  • PWID
  • PWUD

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Policy

Cite this

Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. / Litwin, Alain H.; Soloway, Irene J.; Cockerham-Colas, Lauren; Reynoso, Sheila; Heo, Moonseong; Tenore, Christopher; Roose, Robert J.

In: International Journal of Drug Policy, Vol. 26, No. 10, 01.10.2015, p. 1014-1019.

Research output: Contribution to journalArticle

Litwin, Alain H. ; Soloway, Irene J. ; Cockerham-Colas, Lauren ; Reynoso, Sheila ; Heo, Moonseong ; Tenore, Christopher ; Roose, Robert J. / Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. In: International Journal of Drug Policy. 2015 ; Vol. 26, No. 10. pp. 1014-1019.
@article{327e25d2a33a43f2912a775fceb371ae,
title = "Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program",
abstract = "Background: People who inject drugs (PWID) constitute 10 million people globally with hepatitis C virus, including many opioid agonist treatment patients. Little data exist describing clinical outcomes for patients receiving HCV treatment with direct-acting antiviral agents (DAAs) in opioid agonist treatment settings. Methods: In this retrospective observational study, we describe clinical outcomes for 50 genotype-1 patients receiving HCV treatment with triple therapy: telaprevir (n = 42) or boceprevir (n = 8) in combination with pegylated interferon and ribavirin on-site in an opioid agonist treatment program. Results: Overall, 70{\%} achieved an end of treatment response (ETR) and 62{\%} achieved a sustained virological response (SVR). These treatment outcomes are nearly equivalent to previously published HCV outcomes shown in registration trials, despite high percentages of recent drug use prior to treatment (52{\%}), ongoing drug use during treatment (45{\%}) and psychiatric comorbidity (86{\%}). Only 12{\%} (n = 6) discontinued antiviral treatment early for non-virological reasons. Four patients received a blood transfusion, and one discontinued telaprevir due to severe rash. Conclusions: These data demonstrate that on-site HCV treatment with direct-acting antiviral agents is effective in opioid agonist treatment patients including patients who are actively using drugs. Future interferon-free regimens will likely be even more effective. Opioid agonist treatment programs represent an opportunity to safely and effectively treat chronic hepatitis C, and PWID should have unrestricted access to DAAs.",
keywords = "Direct-acting antiviral agents, HCV, IDU, Injection drug users, PWID, PWUD",
author = "Litwin, {Alain H.} and Soloway, {Irene J.} and Lauren Cockerham-Colas and Sheila Reynoso and Moonseong Heo and Christopher Tenore and Roose, {Robert J.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.drugpo.2015.08.008",
language = "English (US)",
volume = "26",
pages = "1014--1019",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",
number = "10",

}

TY - JOUR

T1 - Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program

AU - Litwin, Alain H.

AU - Soloway, Irene J.

AU - Cockerham-Colas, Lauren

AU - Reynoso, Sheila

AU - Heo, Moonseong

AU - Tenore, Christopher

AU - Roose, Robert J.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: People who inject drugs (PWID) constitute 10 million people globally with hepatitis C virus, including many opioid agonist treatment patients. Little data exist describing clinical outcomes for patients receiving HCV treatment with direct-acting antiviral agents (DAAs) in opioid agonist treatment settings. Methods: In this retrospective observational study, we describe clinical outcomes for 50 genotype-1 patients receiving HCV treatment with triple therapy: telaprevir (n = 42) or boceprevir (n = 8) in combination with pegylated interferon and ribavirin on-site in an opioid agonist treatment program. Results: Overall, 70% achieved an end of treatment response (ETR) and 62% achieved a sustained virological response (SVR). These treatment outcomes are nearly equivalent to previously published HCV outcomes shown in registration trials, despite high percentages of recent drug use prior to treatment (52%), ongoing drug use during treatment (45%) and psychiatric comorbidity (86%). Only 12% (n = 6) discontinued antiviral treatment early for non-virological reasons. Four patients received a blood transfusion, and one discontinued telaprevir due to severe rash. Conclusions: These data demonstrate that on-site HCV treatment with direct-acting antiviral agents is effective in opioid agonist treatment patients including patients who are actively using drugs. Future interferon-free regimens will likely be even more effective. Opioid agonist treatment programs represent an opportunity to safely and effectively treat chronic hepatitis C, and PWID should have unrestricted access to DAAs.

AB - Background: People who inject drugs (PWID) constitute 10 million people globally with hepatitis C virus, including many opioid agonist treatment patients. Little data exist describing clinical outcomes for patients receiving HCV treatment with direct-acting antiviral agents (DAAs) in opioid agonist treatment settings. Methods: In this retrospective observational study, we describe clinical outcomes for 50 genotype-1 patients receiving HCV treatment with triple therapy: telaprevir (n = 42) or boceprevir (n = 8) in combination with pegylated interferon and ribavirin on-site in an opioid agonist treatment program. Results: Overall, 70% achieved an end of treatment response (ETR) and 62% achieved a sustained virological response (SVR). These treatment outcomes are nearly equivalent to previously published HCV outcomes shown in registration trials, despite high percentages of recent drug use prior to treatment (52%), ongoing drug use during treatment (45%) and psychiatric comorbidity (86%). Only 12% (n = 6) discontinued antiviral treatment early for non-virological reasons. Four patients received a blood transfusion, and one discontinued telaprevir due to severe rash. Conclusions: These data demonstrate that on-site HCV treatment with direct-acting antiviral agents is effective in opioid agonist treatment patients including patients who are actively using drugs. Future interferon-free regimens will likely be even more effective. Opioid agonist treatment programs represent an opportunity to safely and effectively treat chronic hepatitis C, and PWID should have unrestricted access to DAAs.

KW - Direct-acting antiviral agents

KW - HCV

KW - IDU

KW - Injection drug users

KW - PWID

KW - PWUD

UR - http://www.scopus.com/inward/record.url?scp=84941802232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941802232&partnerID=8YFLogxK

U2 - 10.1016/j.drugpo.2015.08.008

DO - 10.1016/j.drugpo.2015.08.008

M3 - Article

VL - 26

SP - 1014

EP - 1019

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

IS - 10

ER -